PubMed Health⌕ Search

PubMed · 2085287

[Methamphetamine abuse by smoking].

Abstract

Three cases of methamphetamine abuse by smoking were reported. The oral intake and the intravenous injection of the drug are usually adopted, and the smoking is recently found among the stimulant abusers in Japan. The stimulant is heated on a piece of aluminium foil with a lighter and its smoke is inhaled with a straw or a paper pipe. The intake means are identical to "crystal or ice" in Hawaii, although a special glass pipe or a cigarette is not used here. The effect of the drug obtained by smoking is more slack and mild than that by a intravenous injection, although the drug of the double dose is used in the smoking. Two cases changed the intake means from the injection to the smoking because of no guilty feeling and a lack of injection marks and evident proofs of illegal use. Therefore, abuse of methamphetamine by smoking is thought to increase in near future in Japan, and the delusion of arrest by policemen observed frequently in the stimulant abusers maybe decreases as a result of a decrease in the psychological stress of guilty.

Explore related subjects

Keep this discovery

Explore connections, maps & timelines

BibTeXRIS

S Tohhara, A Kato, T Nakajima. 1990. [Methamphetamine abuse by smoking].. https://pubmed.ncbi.nlm.nih.gov/2085287/

Cite the original work for its findings. Save a collection to share your selection of sources.

KEEP EXPLORING

Related citations

Concurrent carbogen and radiation therapy in children with high-risk brainstem gliomas.

In an attempt to improve local control, we assessed the feasibility of the addition of 4 min of carbogen inhalation (as a radiosensitizer) to daily fractionated radiotherapy in pediatric patients with high grade and/or diffuse brainstem gliomas. Ten patients inhaled carbogen for >90% of the radiation treatments. Median survival time from start of therapy was 0.80 years. Carbogen inhalation did not appear to improve the dismal prognosis.

Administration, Inhalation↗

2. Advances in pharmacotherapy for COPD.

Chronic obstructive pulmonary disease (COPD) is the most common chronic lung disease in the world. In 1999, COPD ranked sixth among the most common causes of death and twelfth as a worldwide burden of disease. It has been estimated that by the year 2020 COPD will be the third leading cause of death and fifth as a worldwide burden of disease. Thus, COPD is a major medical problem and there is evidence that it is increasing throughout the world. Despite recognition of COPD as an important international health problem, COPD has been neglected among common diseases, with little investment in research on its underlying cellular and molecular mechanisms. Recently, global and Japanese guidelines for COPD have been published. These guidelines seem to be useful to improve the underdiagnosis and undertreatment of COPD. In this review, I describe briefly the current recommendation for pharmacological therapy of stable COPD according to the global and Japanese guidelines for COPD.

Administration, Inhalation↗